99 related articles for article (PubMed ID: 95804)
1. Determination of the human lymphokine leukocyte migration inhibitory factor (LIF) by a sensitive radioenzymatic assay. Inhibitory effect of cGMP on the esterolytic activity of highly purified LIF.
Bendtzen K
J Clin Lab Immunol; 1979 Apr; 2(1):37-43. PubMed ID: 95804
[TBL] [Abstract][Full Text] [Related]
2. Use of benzoyl-L-phenylalanyl-L-valyl-L-arginine (3H) methyl ester as a sensitive and selective substrate for the human lymphokine, leukocyte migration inhibitory factor (LIF).
Bendtzen K; Rocklin RE
J Immunol; 1980 Oct; 125(4):1775-81. PubMed ID: 6251137
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte migration inhibitory factor (LIF). IV. 3',5'-cGMP protects LIF against inactivation by the esterase inhibitor phenylmethylsulfonyl fluoride.
Bendtzen K
Scand J Immunol; 1977; 6(12):1357-61. PubMed ID: 203999
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors.
Bendtzen K
Scand J Immunol; 1977; 6(1-2):126-31. PubMed ID: 322258
[TBL] [Abstract][Full Text] [Related]
5. Substrate specificity of the human lymphokine leucocyte migration-inhibitory factor (LIF): radioenzymic assay and inhibition by cGMP.
Bendtzen K
Scand J Immunol; 1979; 10(1):61-7. PubMed ID: 224450
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte migration inhibitory factor (LIF) III. Further investigations on the serine protease nature of this lymphokine and its preference for arginine amides.
Bendtzen K
Scand J Immunol; 1977; 6(10):1055-62. PubMed ID: 335493
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte migration inhibition factor (LIF) increases polymorphonuclear cell endocytosis.
Cortés-Castillo MA; Favila-Castillo L
Arch Invest Med (Mex); 1991; 22(1):35-40. PubMed ID: 1819974
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte inhibitory factor (LIF): a lymphocyte mediator with esteratic properties.
Rocklin R
Fed Proc; 1978 Nov; 37(13):2743-7. PubMed ID: 710595
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte migration inhibitory factor (LIF). II. Partial biochemical characterization of the substrate specificities for this lymphokine.
Bendtzen K
Scand J Immunol; 1977; 6(1-2):133-40. PubMed ID: 322260
[TBL] [Abstract][Full Text] [Related]
10. Amplification of the activity of human leukocyte inhibitory factor (LIF) by the generation of a low molecular weight inhibitor of PMN leukocyte chemotaxis.
Goetzl EJ; Rocklin RE
J Immunol; 1978 Sep; 121(3):891-6. PubMed ID: 690441
[TBL] [Abstract][Full Text] [Related]
11. Leukocyte migration inhibitory factor: a serine esterase released by stimulated human lymphocytes. Kinetic analysis and inhibition by cyclic GMP.
Bendtzen K
Biochim Biophys Acta; 1979 Jan; 566(1):183-91. PubMed ID: 215234
[TBL] [Abstract][Full Text] [Related]
12. Modulation of human T cell production of migration inhibitory lymphokines by cytokines derived from human leukocyte dialysates.
Gottlieb AA; Farmer JL; Matzura CT; Hester RB; Rosenberg JS
J Immunol; 1984 Jan; 132(1):256-60. PubMed ID: 6361122
[TBL] [Abstract][Full Text] [Related]
13. Production of leukocyte migration inhibition factor (LIF) and migration stimulation factor (MStF) by CD4+ and CD8+ human lymphocytes subsets and T-cell clones.
Méndez-Samperio P; Jiménez-Zamudio L; Favila-Castillo L
Rev Invest Clin; 1989; 41(2):107-15. PubMed ID: 2675234
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte inhibitory factor (LIF): two distinct molecular species.
Brown AP; Rocklin RE
J Immunol; 1979 Mar; 122(3):1059-61. PubMed ID: 36430
[TBL] [Abstract][Full Text] [Related]
15. Partial characterization of leukocyte inhibitory factor by concanavalin A-stimulated human lymphocytes (LIF Con A).
Rocklin RE
J Immunol; 1975 Apr; 114(4):1161-5. PubMed ID: 1090666
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors.
Bendtzen K
Scand J Immunol; 1977; 6(1-2):125-31. PubMed ID: 322257
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of the human lymphokine leukocyte migration inhibitory factor (LIF): role of cGMP as a specific inhibitor of the LIF esterase activity.
Bendtzen K
Adv Exp Med Biol; 1979; 114():485-90. PubMed ID: 223417
[No Abstract] [Full Text] [Related]
18. Production of human lymphocyte mediators after activation with periodate or neuraminidase and galactose oxidase.
Greineder DK; Rocklin RE; David JR
J Immunol; 1979 Dec; 123(6):2804-7. PubMed ID: 227960
[TBL] [Abstract][Full Text] [Related]
19. Functional characteristics of histamine receptor-bearing mononuclear cells. I. Selective production of lymphocyte chemoattractant lymphokines with histamine used as a ligand.
Center DM; Cruikshank WW; Berman JS; Beer DJ
J Immunol; 1983 Oct; 131(4):1854-9. PubMed ID: 6352807
[TBL] [Abstract][Full Text] [Related]
20. Increased polymorphonuclear leukocyte cGMP levels induced by the human lympholine, leukocyte migration inhibitory factor (LIF).
Bendtzen K; Klysner R
Immunopharmacology; 1979 Jul; 1(4):323-30. PubMed ID: 233586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
